Carisma Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing macrophage-based cellular therapies, has announced a strategic shift to focus on its in vivo macrophage engineering platform.   To streamline operations and prioritize high-potential programs, the company will discontinue development of its anti-HER2 program, CT-0525, and reduce its workforce by approximately 34%.   “Following a comprehensive review of our portfolio, we have made the strategic d...